The Wegovy 1.7 mg pen: deciding whether this dose is right for you

Where the 1.7 mg pen sits in your treatment, and why that matters

Wegovy's titration schedule runs 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and then 2.4 mg, each step held for roughly four weeks before moving up, though the pace is always agreed with your prescriber rather than followed mechanically. The 1.7 mg pen occupies a particular position: you're close enough to the full maintenance dose that the appetite-regulating effects of semaglutide are meaningful, but you haven't yet reached the level associated with the strongest trial outcomes. The full Wegovy dose schedule covers each step in detail if you want the broader context.

At 1.7 mg, slowed gastric emptying is well established and appetite suppression is noticeable for most people. Some patients find this dose strikes a balance, effective enough to support consistent weight loss, without the gastrointestinal side effects that a step up to 2.4 mg can sometimes bring. That's worth holding in mind as you think about whether to progress.

According to the NHS semaglutide medicines page, the titration schedule exists to help the body adjust gradually, and tolerability at each step is the primary guide. There's no clinical prize for reaching 2.4 mg faster than your body is comfortable with.

The decision most people are weighing at this point in treatment

A question our prescribers hear most weeks is some version of: "I'm on 1.7 mg and feeling well, should I still go up?" The honest answer is that it depends on two things: how you're tolerating the current dose, and how your weight loss is progressing relative to what's clinically expected. Neither of those is something a blog post can settle.

If side effects at 1.7 mg have been significant (persistent nausea, loose stools, or fatigue that hasn't settled) there's a reasonable case for staying at this level while your system catches up. If tolerance is good and loss has plateaued earlier than expected, your prescriber may want to review whether moving to the 2.4 mg pen is the right next step. Pushing up for its own sake isn't the goal; the dose that works sustainably is. For a broader look at how different doses compare on outcomes, this piece on whether higher Wegovy doses work better covers the evidence fairly.

On the cost side of things, private treatment costs vary by dose and provider, the Wegovy cost page sets out what's typical in the UK private market and what a legitimate price should include. That context is worth reading before making any decisions about where to source your treatment.

Side effects at 1.7 mg: what's common and when to seek help

Gastrointestinal effects are the most frequently reported at every Wegovy dose level, and 1.7 mg is no exception. Nausea is the most common; loose stools, constipation, indigestion, and occasional vomiting also feature. For most people these ease within a week or two of reaching a new dose, particularly if meals are smaller and lower in fat during the adjustment window.

Less common but worth knowing: some people report headaches, dizziness, or fatigue in the early weeks at a new dose. These typically resolve without intervention. The injection site itself (abdomen, outer thigh, or upper arm, rotated each week) can occasionally cause redness or mild irritation.

A smaller number of people experience more significant effects. Severe, persistent abdominal pain that spreads toward the back needs prompt medical attention; the MHRA flagged acute pancreatitis as an infrequent but serious risk for GLP-1 medicines in its January 2026 Drug Safety Update. Gallbladder symptoms, signs of dehydration from prolonged vomiting or diarrhoea, and any allergic reaction are also reasons to seek help quickly rather than wait. Diarrhoea on Wegovy is covered in more detail separately if that's been your main concern at this dose.

How a prescriber actually reviews your dose decision

When a prescriber reviews your position at 1.7 mg, they're looking at your reported tolerability, your weight trend since the last review, any new health information, and the full clinical picture, not just a tick-box against a schedule. Moving from 1 mg to 1.7 mg is one review; moving from 1.7 mg to 2.4 mg is another, and both carry the same clinical scrutiny.

At nume, every repeat order (including a dose increase) is reviewed by a GPhC-registered prescriber before anything is dispatched. There are no automated approvals. If you're currently on 1.7 mg and unsure whether to progress, speaking to our prescribers is the straightforward next step: a free consultation, a same-day clinical review, and a clear answer on what makes sense for you specifically.